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Abstract
Background—Pre-exposure prophylaxis (PrEP) is an effective prevention tool for people at 
substantial risk of acquiring human immunodeficiency virus (HIV). To monitor the current state of 
PrEP use among men who have sex with men (MSM), we report on willingness to use PrEP and 
PrEP utilization. To assess whether the MSM subpopulations at highest risk for infection have 
indications for PrEP according to the 2014 clinical guidelines, we estimated indications for PrEP 
for MSM by demographics.
Methods—We analyzed data from the 2014 cycle of the National HIV Behavioral Surveillance 
(NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually 
active. Adjusted prevalence ratios and 95% confidence intervals were estimated from log-linked 
Poisson regression with generalized estimating equations to explore differences in willingness to 
take PrEP, PrEP use, and indications for PrEP.
Results—Whereas over half of MSM said they were willing to take PrEP, only about 4% 
reported using PrEP. There was no difference in willingness to take PrEP between black and white 
MSM. PrEP use was higher among white compared with black MSM and among those with 
greater education and income levels. Young, black MSM were less likely to have indications for 
PrEP compared with young MSM of other races/ethnicities.
Conclusions—Young, black MSM, despite being at high risk of HIV acquisition, may not have 
indications for PrEP under the current guidelines. Clinicians may need to consider other factors 
besides risk behaviors such as HIV incidence and prevalence in subgroups of their communities 
when considering prescribing PrEP.
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Men who have sex with men (MSM) are at increased risk of human immunodeficiency virus 
(HIV) infection. Despite representing only 2% of the US population, MSM accounted for 
65% of estimated HIV diagnoses in the United States in 2013 [1]. Among MSM, blacks are 
disproportionately affected by HIV. In 2010, black MSM accounted for 42% of estimated 
incident HIV infections attributed to male-to-male sexual contact, whereas blacks accounted 
for only about 12% of the US population [2, 3]. The largest number of new infections among 
black MSM (45%) occurred in those aged 13–24 years, and new infections increased 20% in 
this age group from 2008 to 2010 [2]. These data indicate a need for increased HIV 
prevention efforts to further reduce new HIV infections, especially among young, black 
MSM.
Pre-exposure prophylaxis, or PrEP, is an effective prevention tool for people at substantial 
risk of HIV infection [4]. When taken consistently, PrEP has been shown to reduce new HIV 
infections by up to 92% among MSM in randomized trials [5]. The US Food and Drug 
Administration approved a fixed-dose tablet containing tenofovir disoproxil fumarate and 
emtricitabine for use as daily oral PrEP in 2012, and PrEP is now covered by many health 
insurance plans [6]. In 2014, the Centers for Disease Control and Prevention (CDC) 
published clinical practice guidelines for PrEP use in populations at high risk of infection 
based on sexual or injection drug use behaviors [7]. For MSM, PrEP use is recommended for 
HIV-uninfected adults with a male sex partner in the past 6 months, for those who are not in 
a monogamous partnership with an HIV-uninfected man, and for those who meet one of the 
following criteria: condomless anal sex in the past 6 months, a sexually transmitted infection 
in the past 6 months, or an ongoing sexual relationship with an HIV-infected male partner.
The CDC’s National HIV Behavioral Surveillance (NHBS) system monitors HIV-associated 
behaviors, including PrEP use, in MSM and other populations at high risk of HIV infection 
[8]. To monitor the current state of PrEP use among MSM, we report on willingness to take 
PrEP and use of PrEP among participants in the 2014 MSM cycle of NHBS. To assess 
whether the clinical guidelines for PrEP use indicate PrEP for the MSM subpopulations with 
highest HIV incidence and prevalence, we also estimated the number and percentages of 
MSM with indications for PrEP by demographic characteristics.
METHODS
NHBS monitors HIV-associated behaviors and HIV prevalence in 20 cities with high AIDS 
burden among 3 populations at high risk for infection: MSM, people who inject drugs, and 
heterosexual adults at increased risk for HIV infection [8]. Cross-sectional data reported in 
this analysis are from MSM recruited for interviews and HIV testing through venue-based 
sampling (VBS) in 2014. Characteristics of this sample have been previously published [9]. 
NHBS VBS procedures have also been previously published and are briefly summarized 
here [8, 10]. First, staff identified venues frequented by MSM (eg, bars, clubs, gyms, parks, 
street locations, and social organizations) and days and times when men frequented those 
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venues. Venues in which 50% of men attending were MSM were eligible for inclusion. Site 
staff determined venue eligibility through secondary data review, interviews, focus groups, 
or observations. Second, venues and corresponding day/time periods were selected randomly 
for recruitment events. Third, staff members systematically approached men at recruitment 
events to screen for eligibility (aged ≥18 years, lived in a participating city, ever had sex with 
another man, and able to complete the interview in English or Spanish). Interviews were 
conducted by trained interviewers using a standardized questionnaire. NHBS activities were 
approved by local institutional review boards (IRBs) in each participating city. NHBS 
activities were determined to be research in which the CDC was not directly engaged and 
did not require review by the CDC IRB.
MSM with complete and valid interview data who tested HIV negative in NHBS and who 
were currently sexually active, defined as having ≥1 male partner in the past 12 months, 
were included in analyses. Validity was assessed by the interviewer’s confidence in the 
respondent’s answers. Interviewers received in-person training on administering the 
questionnaire, and interviews they marked invalid (16 total interviews [0.2%]) were 
excluded from analysis. The 3 main outcomes were self-reported willingness to take PrEP, 
PrEP use in the past 12 months, and indications for PrEP. Willingness to take PrEP was 
ascertained from the question, “Would you be willing to take anti-HIV medicines every day 
to lower your chances of getting HIV?” PrEP use in the past 12 months was ascertained 
from the question, “In the past 12 months, have you taken anti-HIV medicines before sex 
because you thought it would keep you from getting HIV?” Indications for PrEP were 
adapted from the CDC clinical guidelines and were defined as (1) having ≥2 male partners in 
the past 12 months and either reporting anal sex without a condom or a bacterial sexually 
transmitted disease (STD; ie, chlamydia, gonorrhea, or syphilis) in the past 12 months, or (2) 
having 1 main, HIV-infected male partner in the past 12 months.
Bivariate analyses were conducted to explore differences by demographic characteristics 
(race, age, education, income, and insurance) for the 3 outcomes. We also examined 
differences by sexual behaviors for willingness to take PrEP and PrEP use, but not for 
indications for PrEP, as sexual behaviors were used to define this variable. Adjusted 
prevalence ratios and 95% confidence intervals were calculated from log-linked Poisson 
regression models with generalized estimating equations. Separate models were built for 
each covariate and outcome combination. All models were clustered on VBS recruitment 
event. Covariates associated with the outcomes in bivariate analyses with P values <.10 were 
considered as confounders in the multivariable models and backward elimination was used 
to reduce models. Willingness to take PrEP models was adjusted for age and city. PrEP use 
models were adjusted for race/ethnicity, health insurance, and city. PrEP indication models 
were adjusted for race/ethnicity, age, and city. Analyses were conducted using SAS 
software, version 9.3 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Of 9640 sexually active MSM who consented to an HIV test as part of their participation in 
NHBS, 6847 (71%) tested negative and were eligible for inclusion in analyses. After 
excluding those with missing data (231 MSM missing data on PrEP willingness, 131 
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additional MSM missing data on risks used to assess indications for PrEP, and 2 additional 
MSM missing data on PrEP use), 6483 MSM were left for analysis.
Willingness to Take PrEP
Of 6483 MSM, 3940 (61%) reported willingness to take PrEP (Table 1). There were no 
differences in willingness to take PrEP between Hispanic/Latino and black MSM or between 
white and black MSM, but those of other race were more willing to take PrEP. Younger 
MSM were also more willing to take PrEP. There was no difference in willingness to take 
PrEP by education or annual income, although willingness was slightly more common 
among those without current health insurance. Those who reported a bacterial STD in the 
past 12 months were more likely to be willing to take PrEP than those who did not. 
Willingness was also more common among those with riskier sexual behaviors (eg, more sex 
partners in the past 12 months and condomless anal sex with an HIV-infected partner at last 
sexual encounter with a man). MSM who reported casual male sex partners in the past 12 
months were more likely to be willing to take PrEP compared with those who reported only 
main partners. MSM who had participated in a behavioral intervention in the past 12 
months, meaning that they talked to a counselor or group about HIV prevention apart from 
HIV testing, were more willing to take PrEP as well.
PrEP Use
PrEP use in the past 12 months was not common among participants—only 3.7% used PrEP 
(237/6483), and use varied significantly by demographic and behavioral characteristics 
(Table 1). White MSM were twice as likely to report PrEP use as black MSM. While there 
was no difference by age, those with higher education and current health insurance were 
more likely to use PrEP. PrEP use was also more likely among those who reported 
noninjection drug use or a bacterial STD in the past 12 months. PrEP use increased with 
increasing number of male sex partners in the past 12 months and was most common among 
those who reported both casual and main partners. Those who had condomless anal sex with 
an HIV-infected partner at their last sexual encounter with a man were 5 times as likely to 
have used PrEP in the past 12 months as those who had anal sex with a condom or with an 
HIV-uninfected partner at their last sexual encounter with a man. PrEP use in the past 12 
months varied by city, with a range from 0.5% in San Juan, Puerto Rico, to 11.3% in San 
Francisco, California (Figure 1).
Indications for PrEP
More than half (57%) of MSM who participated in NHBS in 2014 would have an indication 
for PrEP according to our adaptation of CDC guidelines (Table 2). Both white and Hispanic/
Latino MSM were more likely to have an indication for PrEP than black MSM. The 
likelihood of having an indication for PrEP increased with decreasing age. When race and 
age were combined, 65% of young (aged 18–24 years), nonblack MSM had an indication for 
PrEP compared with 55% of young, black MSM. Education, annual income, and current 
health insurance were not associated with having a PrEP indication. When we restricted the 
sample to the 3721 MSM with an indication for PrEP, 216 (5.8%) reported PrEP use.
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Whereas more than half of MSM were willing to take PrEP, only about 4% were actually 
using PrEP in 2014. There was no difference in willingness to take PrEP between black and 
white MSM. Willingness was associated with riskier sexual behaviors, as was PrEP use. 
PrEP use, although low, was higher among white MSM compared with black MSM and 
among those with greater education and income levels. White MSM were also more likely to 
have an indication for PrEP, as were those in younger age groups. Young, black MSM, 
despite being at higher risk of HIV acquisition, were less likely to have an indication for 
PrEP compared with young MSM of other races/ethnicities.
Our findings on willingness to use PrEP are consistent with a recent review of PrEP 
acceptability as measured by willingness [11]. Of 8 studies that offered numerical findings 
on willingness, all reported levels of 50% or higher. While one study included in the review 
found no association between willingness and risk behavior, 4 studies reported an 
association between willingness to take PrEP and unprotected anal intercourse and an 
additional study reported an association between willingness and inconsistent condom use.
PrEP use was most common among San Francisco and Washington, D.C., participants, 
which may be due to their participation in the PrEP Demonstration Project, an open-label 
PrEP delivery project for MSM and transgender women [12]. The project was launched in 
late 2012 and completed enrollment in 2014. Although only a few hundred MSM were 
enrolled at each site (300 in San Francisco, 157 in Miami, and 100 in Washington, D.C.), the 
Demonstration Project likely increased demand for PrEP beyond the participants, as both 
San Francisco and Washington, D.C., had enrollment waitlists throughout the project [13]. 
Miami is also a PrEP Demonstration Project city, but had a much lower prevalence of PrEP 
use among participants in NHBS (1.6%). This may be due to less demand for PrEP in Miami 
compared with the other 2 demonstration cities or to the fact that MSM in Miami were less 
likely to have an indication for PrEP (25% of those approached for the PrEP Demonstration 
Project were ineligible for behavioral or medical reasons in Miami compared with 8% in San 
Francisco and 12% in Washington, D.C.) [13]. In our analysis, MSM in Miami were also 
less likely to have an indication for PrEP (55% compared with 69% in both San Francisco 
and Washington, D.C.; data not shown).
A recent CDC Vital Signs publication that estimated PrEP indications according to the 2014 
guidelines using nationally representative data found that approximately 25% of adult, 
sexually active MSM would have an indication for PrEP to prevent HIV acquisition [14]. 
The estimate of indications for PrEP in NHBS was more than double this estimate, at 57%. 
This difference is likely due to NHBS operating in large urban areas with high AIDS 
prevalence and to the sampling method for MSM, which recruits venue-using MSM who 
may report more risky sexual behaviors compared with the general population of MSM. 
Other reasons for the lower percentage indicated in the nationally representative sample used 
in the Vital Signs analysis could be the lack of data on MSM with an HIV-infected sex 
partner or the lack of inclusion of MSM who inject drugs, both of which likely led to a lower 
percentage having indications for PrEP compared to our analysis. Most MSM (95%) 
recruited for a web-based HIV Behavioral Surveillance System in cities that also conduct 
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NHBS reported attending a venue in the past 12 months and could have been potentially 
recruited to participate in NHBS [15]; we therefore believe NHBS is fairly representative of 
MSM in core urban areas, according to this comparison. Because program planning for PrEP 
rollout is currently occurring in these core urban areas, the NHBS estimate of indications for 
PrEP may be useful for planning purposes.
Our findings on the disparity in PrEP indications by race/ethnicity are consistent with data 
from an observational cohort of HIV-uninfected MSM in Atlanta, which found that 65% of 
black MSM and 88% of white MSM for whom behavioral data were available met 
indications for PrEP based on the criteria in the guidelines [15]. Black MSM were less likely 
to have indications for PrEP in both this analysis and our analysis because they reported 
fewer risk behaviors. Because the increased risk of HIV acquisition for black MSM is 
associated with social determinants such as poverty and racial discrimination rather than 
higher-risk sexual behaviors [15, 16], current clinical guidelines will not indicate PrEP for 
some MSM at highest risk. While the guidelines recommend that clinicians consider 
offering PrEP as one prevention option to “those whose sexual or injection behaviors and 
epidemiologic context place them at substantial risk of acquiring HIV infection” (emphasis 
added) [7], epidemiologic context is not taken into account in the operationalization of the 
guidelines.
A 2012 mathematical model of PrEP impact found that a strategy that targets PrEP to the 
20% of MSM considered to be at highest risk for HIV infection prevented twice as many 
infections over 20 years and at better economic value than a strategy that provides PrEP to 
20% of all HIV-uninfected MSM regardless of risk [17]. In the model, the highest-risk group 
was defined by behavioral risk factors (5 annual partners on average) as well as population-
level factors (initial HIV prevalence of 20% and initial annual incidence of 2.3%). Educating 
providers about how to consider incidence and prevalence data on the MSM subpopulations 
most affected by HIV in their communities together with behavioral indications for PrEP 
could ensure that those at highest risk are offered PrEP.
In addition to being less likely to have indications for PrEP when visiting a healthcare 
provider, it is important to note that significant barriers to accessing healthcare, and 
therefore PrEP, exist for black MSM. Some of the racial disparity in healthcare access is 
attributable to black MSM having lower prevalence of health insurance compared with white 
MSM [15, 18]. If PrEP is then offered more frequently to those who have insurance and 
access healthcare, the existing differences by race/ethnicity in PrEP use and ultimately HIV 
incidence may potentially widen [4]. Ongoing changes in the US healthcare system through 
the Patient Protection and Affordable Care Act of 2010 offer opportunities to improve use of 
clinical preventive services by MSM and to potentially reduce the disparity in healthcare 
access [19]. In the meantime, clinicians and MSM should be informed of the medication 
assistance program and the drug copay program that provide PrEP to uninsured or 
underinsured individuals, respectively (https://start.truvada.com/paying-for-truvada) [20].
Our analyses are subject to several limitations. First, not all of the 2014 PrEP guidelines 
could be matched directly to variables collected in NHBS. We used having ≥2 partners in the 
past 12 months as a proxy for being in a nonmonogamous relationship, but these multiple 
Hoots et al. Page 6













partnerships may not have overlapped in time and may therefore have been monogamous. 
Thus, NHBS data may have overestimated indication for PrEP. Similarly, NHBS variables 
often ask about behavior in the past 12 months, whereas the PrEP guidelines specify a time 
period of the past 6 months, also leading to an overestimation of indications for PrEP. 
Second, NHBS is not a nationally representative sample, so results may not be generalizable 
to all MSM in participating cities or to all cities. Third, our findings are based on self-
reported data and might be subject to social desirability and recall bias. Social desirability 
may lead to overestimation of prevalence estimates for willingness to take PrEP and PrEP 
use, while the direction of bias due to recall error is unknown. Finally, data were not 
weighted to account for the complex sampling methodology used to recruit MSM. Point 
estimates may therefore be biased by over- or underrepresented subgroups of the population.
PrEP use was not common among MSM in NHBS in 2014, although a racial disparity exists 
between black and white MSM with respect to PrEP use in our sample. This disparity may 
be attributable to racial differences in healthcare access rather than a lack of interest in PrEP 
as both black and white MSM reported high willingness to take PrEP. To prevent racial 
disparities in PrEP use, it will be important for clinicians to consider epidemiologic context 
in addition to risk behaviors when considering PrEP indications. This will increase the 
likelihood that PrEP is offered to those at highest risk of HIV acquisition and that the 
greatest impact on HIV incidence is achieved.
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Prevalence of pre-exposure prophylaxis (PrEP) use in the past 12 months by city among 
human immunodeficiency virus (HIV)-uninfected, sexually active men who have sex with 
men in the National HIV Behavioral Surveillance system, 2014. Abbreviations: CA, 
California; CO, Colorado; DC, District of Columbia; FL, Florida; GA, Georgia; IL, Illinois; 
LA, Louisiana; MA, Massachusetts; MD, Maryland; MI, Michigan; NJ, New Jersey; NY, 
New York; PA, Pennsylvania; PR, Puerto Rico; TX, Texas; WA, Washington.
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Table 2
Indications for Preexposure Prophylaxis Among Human Immunodeficiency Virus (HIV)-Uninfected, Sexually 











  Black 1458 782 (53.6) Ref
  Hispanic/Latinod 1812 1052 (58.1) 1.1 (1.0–1.2)
  White 2660 1558 (58.6) 1.1 (1.1–1.2)
  Othere 521 310 (59.5) 1.1 (.9–1.2)
Age, y
  18–24 1492 930 (62.3) 1.5 (1.4–1.6)
  25–34 2518 1564 (62.1) 1.4 (1.3–1.6)
  35–44 1149 646 (56.2) 1.3 (1.2–1.4)
  ≥45 1324 581 (43.9) Ref
Race and age combined
  Black, 18–24 y 457 253 (55.4) Ref
  Black, ≥25 y 1001 529 (52.9) 0.9 (.8–1.0)
  Non-black, 18–24 y 1027 671 (65.3) 1.2 (1.0–1.3)
  Non-black, ≥25 y 3966 2249 (56.7) 1.0 (.9–1.1)
Education
  High school or less 1618 896 (55.4) Ref
  More than high school 4864 2824 (58.1) 1.0 (.9–1.1)
Annual income
  <$20 000 1809 1037 (57.3) Ref
  $20 000–$39 999 1543 901 (58.4) 1.0 (.9–1.0)
  $40 000–$74 999 1652 945 (57.2) 1.0 (.9–1.0)
  ≥$ 75000 1389 792 (57) 1.0 (.9–1.1)
Current health insurance
  Yes 4963 2826 (56.9) 1.0 (.9–1.1)
  No 1508 886 (58.8) Ref
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; PR, prevalence ratio; PrEP, pre-exposure prophylaxis; Ref, reference.
a
Numbers may not sum to total N due to missing values.
b
PrEP indicated defined as having (1) ≥2 male sex partners in the past 12 months AND a bacterial sexually transmitted disease in the past 12 
months or condomless anal sex in the past 12 months, or (2) 1 main HIV-infected partner in the past 12 months.
c
Separate Poisson regression models with generalized estimating equations run for each characteristic of interest; each model included the 
characteristic of interest, race/ethnicity, age, and city; models were clustered on recruitment event.
d
Hispanic/Latinos can be of any race.













Hoots et al. Page 14
e
Includes men who have sex with men reporting American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, other race, or 
multiple races.
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